Comparative Pharmacology
Head-to-head clinical analysis: COLCRYS versus LODOCO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COLCRYS versus LODOCO.
COLCRYS vs LODOCO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Colchicine binds to tubulin, inhibiting microtubule polymerization and thus disrupting cellular functions such as mitosis and neutrophil motility. It also reduces the release of chemotactic factors and decreases the activity of the NLRP3 inflammasome, thereby inhibiting the inflammatory response in gout.
Colchicine binds to tubulin, inhibiting microtubule polymerization, which disrupts mitosis and reduces inflammatory cell chemotaxis, adhesion, and activation. It also inhibits NLRP3 inflammasome assembly and IL-1β production.
For acute gout flares: 1.2 mg orally at first sign of flare, followed by 0.6 mg 1 hour later. Maximum: 1.8 mg per treatment course. For prophylaxis: 0.6 mg orally once or twice daily. Maximum: 1.2 mg/day.
0.5 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 26-31 hours in healthy subjects. In patients with renal impairment, half-life is prolonged (up to 10-13 days in severe impairment), necessitating dose adjustment.
Terminal half-life: approximately 18-24 hours in patients with normal renal function.
Approximately 40-65% of the dose is excreted unchanged in urine (renal excretion) and 10-20% in feces (biliary/fecal elimination). The remainder undergoes hepatic metabolism.
Primarily renal (approximately 50-70% as unchanged drug), with biliary/fecal elimination accounting for 20-30%.
Category C
Category C
Antigout Agent
Antigout Agent